Cancer Therapy via Targeting Warburg Effect Leads to Cancer Metabolism Depression that Promotes Efficient Treatment with Small Dosage Cytotoxic Drugs by Ponizovskiy, Michail R.
  
 
Ivy Union Publishing | http: //www.ivyunion.org September 15, 2014 | Volume 3 | Issue 1  
Ponizovskiy MR et al. American Journals of Cancer Science 2014, 3:30-53 
6 
Page 1 of 24 
 
 
Cancer Therapy via Targeting 
Warburg Effect Leads to Cancer 
Metabolism Depression that Promotes 
Efficient Treatment with Small Dosage 
Cytotoxic Drugs 
 
Michail R. Ponizovskiy 
 
Kiev, “Kiev regional p/n hospital”, Ukraine 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
Research Article 
American Journals of Cancer Science 
http://ivyunion.org/index.php/ajcs/  
Vol 3 Article ID 201400392, 24 pages 
 
 
 
 
 
 
 
 
 
 
 
 
Keywords: MMR proteins; Cellular capacitors; Remote cellular reactions; gene amplification; epigenetic changes 
Peer Reviewer: Shaival K Rao, PhD, Department of Pharmacognosy, C. U. Shah College of Pharmacy & Research, Wadhwan, 
India 
Received: May 8, 2014; Accepted: August 10, 2014; Published: September 15, 2014 
Competing Interests: The authors have declared that no competing interests exist.  
Copyright: 2014 Ponizovskiy M.R. et al. This is an open-access article distributed under the terms of the Creative Commons 
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original auth or 
and source are credited. 
*Correspondence to: Ponizovskiy M.R., “Kiev regional p/n hospital”: Ukraine, Kiev region, Vasilkov district, Voksalna str. 8. 
The present address of M.R.Ponizovskiy: Herschelstrasse 33, 90443 Nuernberg, Germany 
Email: s.olevska@freenet.de 
Abstract  
This work exhibits mechanism of the new method Cancer Therapy via combination “Prolonged medical starvation” with 
considerably decreased dosage of cytotoxic drugs which was described in detail in the article: Ponizovskiy M.R., The detailed 
description mechanisms of the herbs extracts operations in the new method cancer disease treatment via rearrangement of 
metabolism from pathologic development into normal development, Journal of Clinical Trials, 2012, v. 2, Issue 4, 
doi:10.4172/2167-0870.1000124. The mechanism of this method of cancer therapy operates via Warburg effect targeting. The 
purpose of this work is substantiation the supplementary mechanisms of efficient Cancer Therapy via combination “Prolonged 
medical starvation” with considerably decreased dosage of cytotoxic drugs and also substantiation advantage of this method of 
cancer therapy in comparison with cancer treatment with great dosage of cytotoxic drugs. There were described the biochemical and 
biophysical mechanisms of formations resistance to some cytotoxic drugs and recurrence cancer disease after disease remission. 
Also it was described the benefits of use the method “Prolonged medical starvation” with decreased dosage of cytotoxic drugs for 
cancer treatment. The result of this work that it was substantiated the mechanism operation of this method cancer treatment, which 
leads to prevention recurrence cancer disease and resistance to anticancer drugs in comparison with intensive anticancer 
chemotherapy with great dosages of cytotoxic drugs. Also the offered concepts of cancer therapy mechanism gave possibility to 
explain mechanisms of some results of experiments eliminating the doubts of the authors these experiments. As the conclusion, the 
offered method Cancer Therapy should be put into practical medicine after detail clinical trials. 
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1. Introduction 
Austrian folk healer Rudolf Breuss 1992 described the positive results of oncologic diseases treatment 
using “Prolong Starvation during 42 days” [1, 2]. The author was convinced of efficiency of the method 
cancer treatment via “Prolonged medical Starvation 42 – 45 days” by the meetings with cured patients, 
who obtained the folk healer Omelchenko treatment, and determined on own experience of efficiency 
treatment the ill man with the incurable cancer stage as well as testing the factors of this method 
treatment as the experiments on itself. The author has explained the mechanism of this method 
treatment and has substantiated this method treatment, using the offered concept of Warburg effect 
mechanism [3, 4, 5]. The changes, occurring in an organism, have been analysed by the author from the 
point of view of biochemistry and biophysics. The scientific explanation of the mechanism action of 
this method treatment was given using the concept of Warburg effect mechanism [3, 4, 5] (Figure 1). 
Also both the concept of Warburg effect mechanism and the concept of this method treatment 
mechanism were arisen by studies and elucidations of the mechanisms maintenance stability Internal 
Energy and Internal Medium in an organism and in cells of an organism as in normal stationary state as 
well as in quasi-stationary pathologic state of an organism [6, 7, 8]. It was considered the mechanism of 
remote cellular reactions due to cellular capacitors operations, which transit into contact biochemical 
reaction, as for carcinogenesis mechanisms as well as for cancer therapy with Warburg effect targeting 
[9, 10]. Besides, the explanations mechanisms stability of cellular Internal Energy, as in normal 
stationary state of able-bodied cells and as well as in pathologic quasi-stationary states of cancer cells, 
gave possibility to explain mechanism operation “Prolonged medical Starvation” with considerably 
decreased of cytotoxic drugs’ dosage [10]. All of it gave possibility to confirm the advantage this 
method of cancer therapy, which is based on Warburg effect targeting, over some up-to-date methods of 
cancer therapy [4, 5, 10]. Meantime, author gave explanation both the mechanism decrease of medical 
drugs efficiency and mechanism palindromia of cancer recurrence after some medical remissions. Also 
the author noted that the offered method cancer therapy should be put into practice after detail clinic 
trials. Besides, there were explained mechanisms of results some experiments, eliminating doubts 
which were expressed by the authors of these experiments.  
2. Material and Methods 
2.1 Concept of Warburg effect mechanism for substantiation cancer therapy via 
Warburg effect targeting 
Highlight of Warburg effect Concept [3] (Figure 1): As the result of oncogenes operation causing 
enormous anabolic processes in cancer tissue and the enormous consumption of energy and 
Acetyl–CoA for anabolic processes, it takes place the overload of “nodal point of bifurcation anabolic 
and catabolic processes” [NPBac] because of the remained lack of Acetyl–CoA for catabolic oxidative 
processes. Such shift into anabolic processes and lack Acetyl-CoA causes partial suppression of 
catabolic processes in cancer tissue, because some catabolic processes remain for cancer cells survival. 
The increase of lactic acids production is the necessary endoergonic mechanism accumulation of 
energy for huge anabolic processes in condition glycolysis metabolism and enormous consumption of 
energy for anabolic processes in cancer tissue. This concept gives possibility to explain as Warburg 
effect mechanism, elucidating distinction between mechanisms of Pasteur effect and of Warburg effect, 
as well as mechanisms of “Contact inhibition of propagating cells in norm” and of “Absence of 
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contact inhibition of propagating cells in malignant tumor” using also Theorell formula [3]. Besides, 
the offered concept gives possibility to explain the mechanisms of irrepressible tumor growth, 
non-healed cancer ulcer and mechanism of metastases formation [3] (Figure 1). The offered concept 
of Warburg effect mechanism gives possibility to explain as the mechanism operation of “Prolonged 
medical Starvation” from point of view of modern scientific data, and as well as the mechanisms of 
interaction “Prolonged medical Starvation” with considerably decrease dosage of cytotoxic drugs.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.2 The distinctions of mechanisms cellular cycle between an able-bodied tissue/cells and 
cancer tissue/cells which cause maintenance stability Internal Energy and Internal 
Medium of an organism 
Common mechanism of maintenance stability of Internal Energy and Internal Medium as Stationary 
State of an organism in norm as well as Quasi-stationary States of an organism in pathology is divided 
into three levels of regulative mechanism: highest level regulation, high level regulation and low level 
regulation [6, 7, 8] (Figure 2). There are mutual influencing mechanisms maintenance stability 
between an organism and cells of an organism which extend also as between all cells of an organism 
due their capacitors operations as well as between cells and their surrounding medium due to cellular 
capacitors operations for maintenance stability of Internal Medium and an Internal Energy of an 
organism and cells, displaying as immune defensive system [9] (Figure 2). Just the mechanism of 
maintenance stability basophilic chemical potential of cytoplasm (µcytopl) of each cell displays the 
balance of mutual influences between moderately oscillating nDNA fragmentations / reparations in 
nucleus and conformably moderately oscillating mtDNA fusion / fission in mitochondria, which 
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influence on nuclear capacitors and mitochondrial capacitors conformably [10] (Figure 2). The 
interactions between the related resonance waves of the nuclear capacitors and the mitochondrial 
capacitors create the remote reaction for maintenance of stable balance catabolic and anabolic 
processes in cytoplasm which induces stable basophilic chemical potential of cytoplasm (µcytopl) 
defining stable Internal Energy and Internal Medium of cytoplasm in normal quiescent G0 phase of 
cellular cycle [10] (Figure 3).  
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Just oscillating changes of these resisted processes, which occur both in cells and in tissues, are 
mutual subjected due to the central regulation of an organism promoting maintenance stability of 
Internal Energy [stability temperature 36.0°C – 36.9°C by which all enzymes operate] and Internal 
Medium [constant concentration substances in blood and in neurolymph] both in an organism and in 
cells of an organism in norm [10] (Figure 3). Also moderate oscillating shifts of balance anabolic 
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endoergonic and catabolic exoergonic processes into anabolic pathway and into catabolic pathway 
occur in low level of regulatory mechanism for preservation maintenance stability Stationary State of 
an organism. The excessive shift of the balance anabolic endoergonic and catabolic exoergonic 
processes into anabolic endoergonic processes causes Quasi-Stationary State of cancer tissue creating 
the negative fluctuation of entropy according to Glansdorff and Prigogine theory (-∆xβ). The 
Quasi-Stationary State of cancer tissue is characterized by formation Warburg effect, which causes 
excessive proliferative processes, irrepressible cancer growth, unhealed cancer wounds, metastasis 
and cancer cells Apoptosis Resistance [3]. Cancer mitochondria DNA produce abundance quantity 
Reactive Oxygen Species (ROS) in comparison with moderate quantity ROS production in normal 
mitochondria DNA. Just it is known that ROS induces superoxide [O2*-], and superoxide anion is 
subjected to dismutation by manganese superoxide dismutase (MnSOD) and copper, zinc superoxide 
dismutase (Cu, ZnSOD) being converted into hydrogen peroxide [H2O2] [11]. Complex ROS/H2O2 
generates superoxide [O2*] inducing free radicals (*OH) [11]. Free radicals (*OH) react on nucleus 
DNA and induce process replication via realizing of 2nDNA in nucleus, which neutralizes Free 
radicals (*OH) [10]: 
         *OH + H2-nDNA-DNA ––> H2O + H•-nDNA-DNA;  
      O*+ 2H2O ––> 2H• + 2OH¯;   
      2H•-nDNA-DNA + 2H• ––> 2nDNA-H• + 2nDNA-H•;  
      2nDNA-H• + 2*OH ––> 2nDNA + 2H2O 
The great acceleration of cellular cycle, induced by oncogene, is occurred in cancer cells. The part of 
complex ROS/H2O2 in mitochondria is neutralized by glutathione peroxidise (GPX) and phospholipid 
hydroperoxide glutathione peroxidise (PHGPX) in G1 phase oncologic cellular cycle [10, 12, 14, 15, 
16, 17]. The produced excessive abundance of complex ROS/H2O2 in G2 phases oncologic cellular 
cycle pass through mitochondrial membranes and cytoplasm into nucleus and generates excessive 
abundance of superoxide [O2*] inducing excessive abundance of free radicals (*OH). The excessive 
free radicals influence on nuclear DNA inducing processes of permanent DNA replications which also 
cause neutralization of abundance complex ROS/H2O2/Free radicals (equations above) [10]. All 
processes of mitochondrial biogenesis are advanced due to nitric oxide both in normal cellular cycle 
development and in oncologic cellular cycle development exhibiting partial transfer from catabolic 
processes into excessive anabolic processes for cancer cells survival as Apoptosis Resistance that 
cause mechanism aerobic glycolysis of Warburg effect [10, 11, 18, 19, 20, 21].  
2.3 The mechanism operation “Prolonged medical Starvation 42 - 45 days” in cancer 
therapy 
Prolonged medical Starvation as the new approach to cancer therapy activates catabolic processes in 
an organism for maintenance stable temperature 36.0°C-37.5°C by which all enzymes operate. Cancer 
tumor is situated inside the human organism using the organism as Environment, and obtains the 
substances for its metabolism from depot of an organism (fat depots, carbohydrate depots etc.) [4, 5]. 
Also an organism obtains substances for its metabolism from depots of an organism in condition of 
treatment by “Prolonged medical Starvation (during 42-45 days)”. Besides, the treatment by 
“Prolonged medical Starvation (during 42-45 days)” causes considerable decrease almost of all depots 
(especially fat depots) of an organism. Therefore this method treatment leads to the competition 
between cancer tissue and an organism for the use of remained decreased depot in order to maintain 
the normal temperature (36.0ºC-37.5°C) by which the all enzymes operate. The aerobic exothermic 
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oxidation generates the greatest quantity of calories and maintains stability of the normal temperature 
(36.0ºC-37.5°C) of an organism’s Internal Energy, promoting suppression of anabolic endoergonic 
processes in the condition of the treatment by “Prolonged medical Starvation (during 42-45 days)” as 
in the organism as well as in cancer tissue. Thus this competition between the organism and the cancer 
must lead to the win for most strong one. But the protective forces of the organism become stronger 
due to support with herbal extracts, delivering vitamins and microelements into the organism. Also 
increase of fat metabolism from fat depot in condition of “Prolonged medical Starvation (during 
42-45 days)” leads to augmentation glutathione peroxide (GPX) and phospholipid hydroperoxide 
glutathione peroxidise (PHGPX) in all cells of an organism and contributes to neutralization of 
redundant ROS in G1/S phases cellular cycle of cancer cells [10], promoting suppression DNA 
replication due to neutralization of ROS/free radicals in G1/S phases cellular cycle before nDNA 
replication in G2/M phases cellular cycle, as in an organism and as well as in cancer cells. The 
suppression nucleus DNA replication causes suppression of cellular cycle in cancer cells and cessation 
of irrepressible proliferative processes with irrepressible cancer growth. In addition, at the beginning 
of fasting (at 5-7 and 12-14 days) there arises the short acidophilic reaction with formation of ketonic 
bodies as the result of intensive fat oxidation from fat depots of the organism. As the result of 
-oxidation of fat acids many Acetyl ions [CH3CHO-] are produced. The great quantity of Acetyl ions 
increases quantity Acetyl-CoA for catabolic processes that promote partial elimination of overload 
“the nodal point of bifurcation of anabolic and catabolic processes” (NPBac), causing elimination of 
Warburg effect. Acetyl-CoA consumption by the increased oxidative phase of metabolism (Krebs 
cycle) causes the decrease of excess lactic acids which accumulate energy for anabolic processes, 
especially needing for cancer tissue [3, 4, 5]. The cessation of the huge consumption energy and 
Acetyl-CoA for anabolic processes in cancer metabolism ruins the mechanism of Warburg effect and 
restores as balance catabolic and anabolic processes as well as the mechanism of Pasteur effect 
/incompatibility of aerobic processes with glycolysis/ [3, 4, 5]. The cessation of the overload of “nodal 
point of bifurcation anabolic and catabolic processes” [NPBac] promotes the normal excretion of 
synthesized high-molecular substances via oxidative processes and ruins the huge excessive 
Alternative excretion of synthesized high-molecular substances within cancer cells which causes 
metastasis and non-healing tumor ulcers formation [3, 4, 5]. The elimination of the overload of “nodal 
point of bifurcation anabolic and catabolic processes” [NPBac] restores “contact inhibition of cell 
propagation” how in the normal tissue and ruins the irrepressible tumor growth [3, 4, 5]. Thereby 
Warburg effect, characterizing by aerobic glycolysis, is destroyed because of expression aerobic 
catabolic processes and decrease anaerobic processes of glycolysis. Destruction of Warburg effect 
violates cancer metabolism and contributes to normal metabolism via Pasteur effect. 
Thus basic phenomena of the cancer metabolism are inhibited:  
a) Mechanism of “Warburg effect”. 
b) Biochemical and biophysical mechanisms of metastases and non-healing tumor ulcers formation. 
c) The phenomenon of “absence inhibition of contact cell propagation in the metabolism of malignant 
tumor” and as well as irrepressible tumor growth.   
Benefits of the use “Prolonged medical Starvation“ in Cancer therapy: “Prolonged medical 
Starvation” contributes to depression of cancer tumor metabolism that helps efficient anticancer 
therapy with decreased dosage of cytotoxic drugs. Such approach to anticancer chemotherapy 
prevents damage Internal Energy and Internal Medium both an organism and cells of an organism, 
preventing damage of immune and hormonal systems as the links of defensive mechanism in 
regulative system of an organism. Prevention damage of immune and hormonal systems as the links 
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of system stability Internal Energy and Internal Medium an organism prevents recurrence of cancer 
disease after long anticancer chemotherapy and resistance to anticancer drugs in process of intensive 
anticancer chemotherapy with great dosage of cytotoxic drugs.  
Highlight: The huge anabolic processes with huge consumption of energy and Acetyl-CoA are 
characteristic for cancer tissue. These processes suppress the catabolic exoergonic processes in cancer 
tissue retaining only the rest catabolic exoergonic processes for cancer cells survival. Just “Prolonged 
medical Starvation“  induces shift balance catabolic and anabolic processes of tissue metabolism into 
expression of catabolic exoergonic processes for maintenance stability of Internal Energy of the 
organism (the stable temperature an organism 36.0°C – 37.5°C; stable parameters of PH and osmotic 
pressure etc. in blood and in neurolymph), that suppress anabolic endoergonic processes of cancer 
tissue leading to tumor depression [3, 4]. “Prolonged medical Starvation” promote suppression DNA 
replication, due to ROS/free radicals neutralization in G1/S phases cellular cycle before nDNA 
replication in G2/M phases cellular cycle, as in an organism and as well as in cancer cells. The 
suppression nucleus DNA replication causes suppression of cellular cycle in cancer cells and cessation 
of irrepressible proliferative processes with irrepressible cancer growth. The use light cytotoxic herbal 
extract in condition of Prolonged medical Starvation leads to transition of tumor depression into 
damage of tumor metabolism and to cure of the patient.   
2.3.1 The mechanism operation of the herbs extracts in new method of cancer treatment 
Considering the above described mechanism operation of the treatment by “Prolonged medical 
Starvation during 42-45 days”, this method of cancer treatment leads to depression of development 
tumor as the result of damage the main mechanisms of cancer tumor metabolism. The crucial role of 
maintenance Internal Energy stability of the organism in condition of Prolonged medical Starvation 
appertains to the all tendered extracts of herbs as well as to the Vegetable Juice Mixture, which deliver 
to an organism necessary microelements and vitamins, especially folic acid, that is necessary for 
hemopoiesis, and decreases also acidification in the blood of the organism. It needs to pay the especial 
attention to the extract of red cranesbill (Geranium robertianum) which contains significant amounts 
of Vitamins A, B and C as well as such minerals: calcium, potassium, magnesium, iron, phosphorus, 
germanium, according to Shipard Isabell [22]. Besides, R.Breuss notes that red cranesbill (Geranium 
robertianum) contains the small quantity of radium [1, 2]. Also Shipard Isabell [22] notes that 
Geranium (or Herb Robert) has wide range of clinical applications as remedy with such properties: 
antibiotic and antiviral properties, sedative property, tonic, astringent, diuretic, digestive, antioxidant. 
Thus it should be paid attention to especial importance that Geranium (or Herb Robert) is a source of 
germanium [22] and radium [1, 2]. Also taking into account that red cranesbill (Geranium 
robertianum) has antibiotic and antiviral properties [22], it can assume that red cranesbill (Geranium 
robertianum) has also light cytotoxic property due to content of radium which cytotoxic properties 
don’t raise the doubts. Thus it can assume that red cranesbill (Geranium robertianum) causes light 
cytotoxic property on depressed malignant tumor in condition of Prolonged Starvation 42 – 45 days, 
promoting cancer disease treatment and cure of patient. Such light cytotoxic property can not make 
negative influence on immune and hormonal systems of an organism essentially as opposed to 
chemotherapy with great dosage cytotoxic drugs.  
2.3.2 The some footnotes concerning method of “Prolonged medical Starvation 42 - 45 
days” in cancer therapy 
The method cancer treatment via “Prolonged medical Starvation 42 - 45 days” and results of practical 
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observations were described in detail in the article: Ponizovskiy M.R., The detailed description 
mechanisms of the herbs extracts operations in the new method cancer disease treatment via 
rearrangement of metabolism from pathologic development into normal development, Journal of 
Clinical Trials, 2012, v. 2, Issue 4, doi:10.4172/2167-0870.1000124 [5].  
There are the short description and explanation of preliminary preparation for following use cancer 
treatment via “Prolonged medical Starvation during 42 - 45 days” [4, 5, 10].  
Prologed medical Starvation should be supplemented by considerably decreased dosage cytotoxic 
substances! “Prolonged medical Starvation during 42 - 45 days” should be defended with the support 
of herbs extracts [sage, hawthorn, horse-tail, (stinging-)nettle, ninety-knot, hypericum, ergot, St.John’s 
wort, etc.] providing with cytotoxic activity of red cranesbill (Geranium robertianum) and used 
abundant liquid drink including water up to 1,5 – 2,0 liter per day. The herbal extracts should be 
filtered through a triple gauze layer in order that any fibre mustn’t remain in the extract. The herbal 
extracts fill the organism with necessary microelements and vitamins, especially folic acid, that is 
necessary for hemopoiesis and decreases also acidification in the blood of the organism by “Prolonged 
medical Starvation”. During the “Prolonged medical Starvation” it’s necessary to look after the 
common health state of the person and especially state of gastrointestinal tract that it occurs the 
bowels open /timely evacuation of excrements/, that there will not be constipation /retention of feces/. 
The disturbance of gastrointestinal activity should be healed with vegetable laxatives, activated 
charcoal, medicaments and use an enema if it’s necessary. The starvation leaving should been taken 
place during 7 days with gradual addition of products: juices, then watery decoctions and gels, then 
vegetable pulps, then baked fruits and vegetables, then liquid kasha (dish of cooked grain), then 
mashed potatoes, then pair of cutlets – and up to the usual nutrition. The diet shouldn’t be salted 
during leaving starvation. 
The contraindications to the use of “Prolonged medical Starvation 42 - 45 days”.  
The irreparable cancerous damage of Internal Energy and Internal Medium an organism are the basis 
of the contraindications to the use of the offered method cancer treatment. So the generalized 
excessive shift of balance anabolic and catabolic processes into the huge anabolic processes via 
abundant metastasis suppresses catabolic processes critically. Just catabolic processes generate energy 
and dissipate energy into environment promoting stability energy [36.6ºC – 37. 3ºC] for maintenance 
stability Internal Energy an organism, i.e. catabolic processes contribute to survival of an organism. 
Thus aggressive processes of metastatic disease create Apoptosis Resistance in cancer cells and 
enhance apoptotic processes in an organism. These destructive processes in the organism lead to 
damage of Internal Energy of the organism, i.e. the symptoms which are the contraindication to the 
use Prolonged medical starvation [42 – 45 days].  
Thus there are the contraindications to the use of the offered method cancer treatment:  
* Cachexia is the first cause of contraindication to the use of the offered method cancer treatment, 
because progressive loss of weight indicates the full downfall of energy forces of the organism and 
also full downfall of its defensive system, promoting irrepressible development of cancer tumor. 
Considering such physical state of the organism, the prolonged medical starvation can not deprive 
cancer tissue of substances for cancer metabolism. 
* Full frailty of the organism is the second cause of contraindication to the use of the offered method 
cancer treatment. This contraindication shows symptoms both unstable equilibrium state of body and 
helplessness of the person. Full frailty also indicates the full downfall of energy forces of the 
organism and also full downfall of its defensive system, promoting irrepressible development of 
cancer tumor. Considering such physical state of the organism, the prolonged medical starvation can 
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not deprive cancer tissue of substances for cancer metabolism. 
* Cancerous intoxication due to the decomposition of cancerous necrotic mass is the third cause of 
contraindication to the use of the offered method cancer treatment. Cancerous intoxication becomes 
apparent as sickness with uncontrollable vomiting, anorexia and bad physical state of the organism. 
Cancerous intoxication indicates irrepressible development of cancer tumor owing to the full downfall 
of energy forces of the organism and also full downfall of its defensive system. Considering such 
physical state of the organism, the prolonged medical starvation can not deprive cancer tissue of 
substances for cancer metabolism. 
* Dangerous metastasis for life is the fourth cause of contraindication to the use of the offered method 
cancer treatment. There are such dangerous for life metastasis: metastasis in brain, metastasis in spinal 
marrow, vast metastasis in liver causing huge liver and so on.  
* The tumors, which create emergency needing to urgent medical /especial surgical/ help, should not 
be treated with prolonged medical starvation of the new method cancer treatment before rendering 
first aid of urgent medical - surgical help. There are such emergency situations: large bowel 
obstruction [ileus], urinary obstruction, biliary tract obstruction, airways obstruction, duodenal 
obstruction, small bowel obstruction, and tumor location in vital center or in vital organs which can be 
ablated by surgical methods. It is the fifth cause of contraindication to the use of the offered method 
cancer treatment.  
3. Resuts 
3.1 Advantage action of small dosage cytotoxic drugs on depressed cancer 
metabolism for prevention cancer disease recurrence and drugs resistance 
to the cytotoxic effects in offered method cancer treatment over action of 
great dosage cytotoxic drugs in modern methods cancer therapy 
Unlike the modern methods of cancer disease treatment the offered method of cancer disease 
treatment via “Prolonged medical Starvation with very small dosage cytotoxic drugs” does not intrude 
into immune and hormonal systems and does not violate the stability as an organism Internal Energy 
and Internal Medium as well as cells of an organism, at the same time causing the violation of cancer 
tumor metabolism. Therefore the offered method of cancer disease treatment via “Prolonged medical 
Starvation with very small dosage cytotoxic drugs” does not result in appearance of epigenetic 
changes and genes amplification causing drugs resistance to the cytotoxic effects and does exert cancer 
disease recurrence after some medical remissions which occur as the result of damage both immune 
and hormonal systems by great dosage cytotoxic drugs using in up-to-date methods cancer therapy. 
However the combination of the described offered method treatment with up-to-date methods cancer 
treatment should be approved in clinical condition as Clinical Trials. 
Highlight: The inhibition of proliferative anabolic properties of cancer cells is achieved via the 
rearrangement of cancer metabolism from anabolic pathway into catabolic pathway in the treatment via 
“Prolonged medical Starvation”. Thus this method cancer treatment puts cancer metabolism into state 
of depression and preserves proliferative anabolic functions of immune and hormonal system and as 
well as Internal Energy and Internal Medium an organism. The light cytotoxic effect of small dosage of 
anticancer drugs in condition of cancer depression does not exert mechanism of drugs resistance to the 
cytotoxic effects and recurrence cancer disease after remission of cancer disease, but lead to destruction 
cancer metabolism and recovery of ill man.   
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4. Discussion of the benefit combination “Prolonged medical 
Starvation” with the decreased dosage cytotoxic drugs for 
efficient cancer therapy 
4.1 Discussions of mechanisms drugs resistance to the cytotoxic effects due 
to the intensive course of treatment with the great dosage of cytotoxic 
therapy 
4.1. 1 Mechanism of Cordycepin (3'-deoxyadenosine) cytotoxic effect.  
Describing mechanism of Cordycepin (3'-deoxyadenosine) cytotoxic effect, Imesch P. et al. [23] 
researched Cordycepin cytotoxic effect via study both transcription processes as an inhibitor of poly(A) 
polymerase (PAP) and DNA replication focused on MLH1 [one of the five DNA mismatch repair 
(MMR) proteins], i.e. processes which operate in G2/M phases of cellular cycle. Also they noted that 
cells with defective MMR function showed resistance to certain anticancer drugs. So Imesch P. et al. 
[23] found that MLH1-deficient tumor cells exhibited reduced susceptibility to apoptosis upon 
treatment with cordycepin, as compared to MLH1-proficient tumor cells.  
Also studying cytotoxic effect of Lipoplatin (a novel liposomal cisplatin exhibiting highly effective 
action against cancers), Fedier A., Poyet C, et al. [24] revealed that MLH1-deficient tumor cells were 
less susceptible to apoptosis than MLH1-proficient tumor cells. However they noted that 
MLH1-deficient tumor cells showed the same sensitivity to lipoxal (a novel liposomal drug – 
oxaliplatin) as well as MLH1-proficient tumor cells. Besides Sergent C. et al. [25] have supposed that 
high-level resistance of human colon cancer cells to high doses of cisplatin and oxaliplatin does not 
seem to be related to acquired defects in the DNA MMR proteins.  
a. Mechanisms of experiments outcomes: Cancer tissue metabolism is characterized by huge 
anabolic processes, promoting irrepressible proliferative processes via advance G1/S phases of cellular 
cycle [3, 8, 10]. Development cellular cycle requires mismatch repair (MMR) proteins (enzymes) for 
repairs of base-base mismatch, that occur due to DNA replication in G2/M phases cellular cycle as in 
MLH1-proficient tumor cells as well as in MLH1-deficient tumor cells. Therefore it can be such case 
by MLH1-deficient tumor cells that the function repair of DNA mismatch is distributed as among the all 
mismatch repair (MMR) proteins (nine genes of MMR function) as well as among the main five genes 
of MMR function (MLH1, PMS1, PMS2, MSH2, and MSH6). Thus the operative area of the cytotoxic 
drugs become wider and their cytotoxic effects are divided among these proteins decreasing dosage of 
cytotoxic drugs on each protein and also decreasing susceptibility to apoptosis upon treatment with 
these drugs. Only strong cytotoxic drugs with cytotoxic influence on both anabolic processes and 
catabolic processes in both G1/S and G2/M phases cellular cycle show the similar cytotoxic effects in 
both MLH1-deficient tumor cells and MLH1-proficient tumor cells. Besides there is the other 
mechanism: Remote cellular reactions between cells and cytotoxic drug, which are carried out by 
system of cellular capacitors exhibiting interplay between nucleus capacitors, mitochondria capacitors 
and other organelle capacitors connecting with cellular capacitors, precede cellular contact reactions 
with substances of cytotoxic drugs [9]. Remote cellular reactions set cells to accept the substance of 
cytotoxic drug. Also remote reactions cells cause attraction between cells and substance of cytotoxic 
drug which can be weaker in MLH1-deficient tumor cells than in MLH1-proficient tumor cells due to 
violation interactions between nDNA and mtDNA, resulting in violation operations of nucleus 
capacitors – mitochondria capacitors link that influence on stability basophilic chemical potential 
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cytoplasm and on cellular inner membrane charge of cellular capacitors [9, 10]. Therefore the remote 
cellular reaction between MLH1-proficient tumor cells and cytotoxic drug can be more absolute than 
with MLH1-deficient tumor cells. Hence the acting of cytotoxic drug in contact reaction with 
MLH1-proficient tumor cells can be greater than with MLH1-deficient tumor cells. Thus 
MLH1-deficient tumor cells can be less susceptible to cytotoxic drug and to apoptosis than 
MLH1-proficient tumor cells, i.e. drug resistance occurs in MLH1-deficient tumor cells. On the other 
hand, the interactions between remote cellular reactions and contact cellular reactions show the 
following sequence of the reactions between cells and cytotoxic drug: Cellular capacitors react on 
substance of cytotoxic drug and promote reaction of cells on cytotoxic drug [9]. Simultaneously 
mutual interactions between cellular capacitors and link of nucleus capacitors – mitochondria 
capacitors promote rearrangement mismatch repair (MMR) function in nucleus, connecting with 
molecular structure of cytotoxic drug substance. Such rearrangement mismatch repair (MMR) function 
in nucleus can lead to such case that the operative area of the cytotoxic drug become wider due to 
distribution of the function reparations of DNA mismatch as among the all mismatch repair (MMR) 
proteins (nine genes of MMR function) as well as among the main five genes of MMR function (MLH1, 
PMS1, PMS2, MSH2, and MSH6) in MLH1-deficient tumor cells. Thus the drug cytotoxic effect in 
MLH1-deficient tumor cells is divided among the mismatch repair (MMR) proteins decreasing dosage 
of cytotoxic drug on each protein and also decreasing susceptibility to apoptosis upon treatment with 
this drug. 
b. Footnote: The advantage of the combination very light cytotoxic effect of the small dosages of 
cytotoxic drugs [Cordycepin, Cisplatin, Lipoplatin, Lipoxal (oxaliplatin) etc.] with the offered method 
cancer disease treatment is that the offered method cancer disease treatment  leads to depression of 
cancer tumor metabolism due to suppression anabolic processes, and the cytotoxic effects of the small 
doses drugs become stronger over the suppressed anabolic processes of cancer tumor with great 
dosage cytotoxic drugs in the state of cancer cells activity in modern methods cancer therapy. Just the 
great dosages of cytotoxic drugs show the similar cytotoxic effects as on hormonal cells and immune 
cells of an organism’s defensive function as well as on both MLH1-deficient tumor cells and 
MLH1-proficient tumor cells, i.e. they interfere in Internal Medium an organism suppressing 
defensive function of an organism.  
4.1.2 The influences of PI3K/AKt cascade inhibitors on efficiency of cytotoxic effects 
caused by medical drugs and focused on MLH1-deficient tumor cells or on 
MLH1-proficient tumor cells  
Ohta T. et al. [26] and Stathopoulos G P and Boulikas T [27] note that the PI3K/Akt cascade displays 
an important role in the resistance of ovarian cancer cells to cisplatin.  
Fedier A et al. [28] investigated interdependence between cytotoxic effect of lipoplatin and AKt 
inhibitor LY294005. Their outcomes showed that LY294005 /inhibitor of AKt/ decreases the efficacy 
of cisplatin, lipoplatin, oxaliplatin as well as lipoxal in human colorectal adenocarcinoma, but, unlike 
these drugs, LY294005 increases the efficacy of Docetaxel and does not affect the efficacy of 
6-thioguanine. Fedier A et al. [28] prolonged the study of mechanisms AKt inhibition by LY294005 
investigating the function of DNA mismatch repair (MMR) in MLH1-deficient tumor cells and in 
MLH1-proficient tumor cells. The results of researches show that the influence of LY294005, resulting 
in decreases efficiency with Cisplatin and Lipoplatin, is significantly higher in the MLH1-deficient than 
in the MLH1- proficient, but nearly similar efficiency with Oxaliplatin and Lipoxal. Moreover 
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LY294005 in the MLH1-deficient increases sensitivity with Docetaxel and decrease sensitivity with 
platinum compounds drugs that can not be associated with the concomitant deletion of the 
phospho-Aktser473 level. On the contrary, analogous changes in drug sensitivity were observed with 
the PI3-kinase inhibitor LY294002, but these changes were associated with complete deletion of 
phospho-Aktser473. Fedier A et al. [28] suppose a possible relationship between MMR-mediated with 
cisplatinum DNA damage and action AKt, e.g. a common target for both pathways. Simultaneously 
Fedier A et al. [28] express desire that the possible new property of Akt in making influences on drug 
sensitivity may also be proposed.  
a. Mechanisms of experiments outcomes: AKt stimulates glycolysis activating hexokinase 2 
(HK-2), i.e. AKt promotes the first an irreversible step in glycolysis, according to Elstrom RL et al. 
[29] and Gottlob K et al. [30]. Besides, Akt promotes growth factor, according to data Plas DR et al. 
[31, 32]. Just Akt pathway leads to produce Acetyl-CoA via stimulating glucolisis. Thus AKt 
stimulates both anabolic endoergonic pathway and catabolic exoergonic pathway which are formed 
from Acetyl-CoA of “nodal point bifurcation of anabolic endoergonic processes and catabolic 
exoergonic processes” /NPBab/ [3, 4] (Figure 1). Cisplatin and Lipoplatin damage cellular nucleus, 
violating nuclear basis of anabolic processes. However they do not put obstacles in the AKt operation 
of inducing catabolic exoergonic processes and anabolic endoergonic processes via glycolysis in 
cytoplasm. Really it is possibility that LY294005 /inhibitor of AKt/ decreases the efficacy of cisplatin, 
lipoplatin, oxaliplatin due to relationship between MMR-mediated with cisplatinum DNA damage and 
action PI3K/AKt inhibitors. Just both AKt inhibitor LY294005 and PI3-kinase inhibitor LY294002 
violate glycolysis in cytoplasm that cause violation of mismatch repair (MMR) function due to lack of 
Acetyl-CoA, violating in both anabolic function (connected with nucleus function) and catabolic 
function (connected with mitochondrial oxidative function) and converting cells into MLH1-deficient 
tumor cells. Thus mechanisms operations of these drugs show that they more decrease activity in 
MLH1-deficient tumor cells than in MLH1-proficient tumor cells, because the function repair of DNA 
mismatch is distributed in MLH1-deficient tumor cells as among the all mismatch repair (MMR) 
proteins (nine genes with MMR function) as well as among the main five genes with MMR function 
(MLH1, PMS1, PMS2, MSH2, and MSH6). Therefore the operative area of these cytotoxic drugs 
become wider and their cytotoxic effects are divided among these proteins decreasing dosage of 
cytotoxic drug on each protein and also decreasing susceptibility to apoptosis upon treatment with these 
drugs in MLH1-deficient tumor cells. Docetaxel exhibits also strong anti-mitotic chemotherapy, i.e. 
Docetaxel violates both nuclear function and mitochondrial function. Therefore LY294005 in the 
MLH1-deficient increases sensitivity with Docetaxel and decrease sensitivity with platinum 
compounds.  
b. Footnote: Taking into account these researches it can affirm that the advantage of the 
combination very light cytotoxic effects of the small dosages of cytotoxic drugs [Cisplatin, Lipoplatin, 
Docetaxel etc.] with the offered method cancer disease treatment is similar to above described 
mechanism suppression depressed cancer metabolism with small dosage of cytotoxic drugs over 
suppression active cancer metabolism with great dosage cytotoxic drugs in up-to-date methods of 
cancer therapy which cause interference in Internal Medium of an organism suppressing defensive 
function of an organism.  
4.1.3 Influence of radicicol, heat shock protein 90 (HSP90) inhibitor, on sensitivity to 
cisplatin in presence of MLH1 protein 
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Fedier A at al. [33] have researched the influence of radicicol, heat shock protein 90 (HSP90) inhibitor, 
on sensitivity to cisplatin in presence of MLH1 protein. Their data demonstrated that radicicol increased 
the sensitivity to cisplatin and to oxaliplatin in both MLH1-proficient cells and MLH1-deficient cells, 
but considerably higher in MLH1-proficient cells than in MLH1-deficient cells. Considering data that 
radicicol is a novel specific inhibitor for heat shock protein 90 (HSP90), they have supposed a possible 
functional relationship between HSP90 and MLH1, where HSP90 might affect the function of MLH1 in 
a way that this leads to the counter-regulation of cytotoxic pathways initiated by MMR as a 
consequence of the presence of DNA damage introduced by cisplatin.  
a. Mechanisms of experiments outcomes: Here is the mechanism decrease generating energy for 
maintenance stability of Internal Energy an organism (stable temperature 36.6°C -37.2°C by which all 
enzymes operate) in condition of high temperature in environment: Catabolic processes of glycolysis 
carry out peculiar functions, unlike the subsequent catabolic processes after “nodal point bifurcation 
of anabolic and catabolic pathways [NPBac]” [3]: Just catabolic processes of glycolysis generate 
energy. This energy is divided into anabolic and catabolic processes in “nodal point of bifurcation 
anabolic and catabolic processes” [NPBac], also the part of this energy is cumulated into Lactic acids 
for anabolic processes [3]. Thus glycolysis is the primer for both catabolic and anabolic processes. 
The subsequent catabolic processes, which are formed as the result bifurcation of anabolic and 
catabolic processes in NPBac, dissipate energy into environment for maintenance stable Internal 
Energy an organism, i.e. temperature 36.6°C – 37.0°C by which all enzymes operate in an organism. 
The stable temperature 36.6°C – 37.0°C by which all enzymes operate in condition of high 
temperature in environment demands of suppression generating energy via inhibition glycolysis. Thus 
the heat shock protein 90 (HSP90) takes part as the link in mechanism inhibition of glycolysis in 
condition of high temperature in environment, i.e. condition of the heat shock. However the 
maintenance stable temperature 36.6°C – 37.0°C by which all enzymes operate in normal temperature 
condition occurs via suppression of shock protein 90 (HSP90). It is achieved by radicicol as inhibitor 
heat shock protein 90 (HSP90). Therefore it is a possible consequence of counter-relationship between 
HSP90 and radicicol, which influences on balance catabolic and anabolic processes, i.e. on anti- and 
pro-proliferative pathways via suppression and expression of glycolysis: The radicicol induces 
pro-proliferative pathway in G2/M phases cellular cycle inhibiting HSP90 as well as MLH1. Just the 
replicative bypass in drug resistance mediated by loss of MMR can occur due to interactions between 
heat shock protein 90 (HSP90) or p53 (anti-proliferative pathways) and mismatch repair (MMR) 
mechanisms (pro-proliferative pathways). The possible functional counter-relationship between HSP90 
and mismatch repair (MMR) mechanisms reflects counter-relationship between HSP90 and radicicol. 
Just the suppression both catabolic and anabolic processes is characterized for HSP90. On the contrary, 
the function of mismatch repair (MMR) mechanisms is characterized by maintenance anabolic 
reparative processes for the advance of G2/M phases of cellular cycle. Just influence of radicicol repairs 
the mismatch repair (MMR) function. Therefore suppression of HSP90 by radicicol impels mismatch 
repair (MMR) function, which sensitivity to cisplatin and to oxaliplatin is increased in both 
MLH1-proficient cells and MLH1-deficient cells. However sensitivity to cisplatin and to oxaliplatin is 
considerably higher in MLH1-proficient cells than in MLH1-deficient cells, because the function 
mismatch reparations (MMR) of DNA in MLH1-deficient cells distribute as among the all mismatch 
repair (MMR) proteins (nine genes with MMR function) as well as among the main five genes with 
MMR function (MLH1, PMS1, PMS2, MSH2, and MSH6). Thus the operative area of the cytotoxic 
property of cisplatin or oxaliplatin become wider and the cytotoxic effects are divided among the 
mismatch repair (MMR) proteins decreasing dosage of cisplatin cytotoxic effect on each protein and 
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also decreasing sensitivity to cisplatin or to oxaliplatin, showing more resistance to cytotoxic drugs in 
MLH1-deficient tumor cells than in MLH1-proficient tumor cells.  
b. Footnote: The advantage of the combination very light cytotoxic effects of the small dosages of 
cytotoxic drug (cisplatin or oxaliplatin) with the offered method cancer disease treatment is that the 
offered method cancer disease treatment leads to depression of cancer tumor metabolism due to 
suppression anabolic processes, i.e. suppression of mismatch repair (MMR) function via partial 
expression HSP90 function. However the peculiarity of cancer treatment mechanism confirms that the 
advantage of the combination very light cytotoxic effects of the small dosages of cytotoxic drug 
(cisplatin or oxaliplatin) with the offered method cancer disease treatment is similar to above 
described mechanism suppression depressed cancer metabolism with small dosage of cytotoxic drugs 
over suppression active cancer metabolism with great dosage cytotoxic drugs in up-to-date methods of 
cancer therapy.  
4.1.4 Role of MMR (human MLH1(-) and MMR-deficient in cellular responses to 5-fluorouracil 
and 5-fluoro-2'-deoxyuridine (FdUrd) 
Meyers M et al. [34] have investigated the role of MMR (human MLH1(-) and MMR-deficient of 
HCT116 colon cancer cells) in cellular responses to 5-fluorouracil and 5-fluoro-2'-deoxyuridine 
(FdUrd). They have determined that HCT116 3-6 cells treated with a low dose of FdUrd have a 2-fold in 
response to cytotoxic agents: the G2 cell cycle arrested with MMR-deficient cells of HCT116 is 
compared to enhanced G2 cell cycle in MMR-proficient cells.  
a. Mechanisms of experiments outcomes: A low dose of FdUrd had a 2-fold in response to 
cytotoxic agents: G2 cell cycle is arrested with MMR-deficient owing to distribution of cytotoxic effect 
with MMR-deficient of HCT116 cells among the all mismatch repair (MMR) proteins, unlike enhanced 
G2 cell cycle in MMR-proficient cells. Just remote cellular reactions set cells to accept the substance 
of cytotoxic drug. Also remote cellular reactions cause attraction between cells and substance of 
cytotoxic drugs which can be depressed in MLH1-deficient tumor cells more than in MLH1-proficient 
tumor cells due to violation of link nucleus capacitors – mitochondria capacitors influencing on 
cellular capacitors [9, 10]. Therefore the remote cellular reaction between cells and cytotoxic drugs 
with MLH1-proficient tumor cells can be more absolute than with MLH1-deficient tumor cells. Hence 
the cytotoxic drugs in contact reaction with MLH1-proficient tumor cells can show greater cytotoxic 
effect than with MLH1-deficient tumor cells. Thus MLH1-deficient tumor cells can be less 
susceptible to cytotoxic drug and to apoptosis than MLH1-proficient tumor cells, i.e. drug resistance 
occurs more in MLH1-deficient tumor cells.  
b. Footnote: The advantage of the combination very light cytotoxic effects of a low dose of 
cytotoxic drug (FdUrd) with the offered method cancer disease treatment is that the offered method 
cancer disease treatment leads to depression of cancer tumor metabolism due to suppression anabolic 
processes, i.e. suppression of mismatch repair (MMR) function and partial expression catabolic 
function for cells survival. However it can affirm that the advantage of the combination very light 
cytotoxic effects of the small dosages of cytotoxic drug (FdUrd) with the offered method cancer 
disease treatment is similar to above described mechanism destruction depressed cancer metabolism 
with small dosage of cytotoxic drugs over suppression active cancer metabolism with great dosage 
cytotoxic drugs in up-to-date methods of cancer therapy.  
4.1.5 Role bypass of DNA replication pathway in drug resistance mediated by loss of MMR  
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The interesting investigations were made by Moreland NJ et al. [35]. They have used aphidicolin (Ap), 
an inhibitor of DNA polymerases, to study the role bypass of DNA replication pathway in drug 
resistance mediated by loss of MMR and received aphidicolin (Ap) for sensitizing drug-resistant cancer 
cells, that is characterized for loss MMR. Just their experiments showed bypass of DNA replication 
pathway in drug resistance in situation of loss MMR, i.e. mechanism of drug resistance. 
a. Mechanisms of experiments outcomes: The outcomes of these experiments confirm that the 
DNA reparative function by loss of MMR and received aphidicolin (Ap) (an inhibitor of DNA 
polymerases) occurs via bypass of DNA replication pathway, i.e. it can be connected as with loss of 
MMR functional because this function reparation is distribute as among the all mismatch repair (MMR) 
proteins (nine genes with MMR function) as well as among the main five genes with MMR function 
(MLH1, PMS1, PMS2, MSH2, and MSH6) exhibiting bypass anabolic MLH1 proliferative functions. 
Also bypass of DNA replication function depends on cellular capacitors [9, 10], i.e. drug resistance, 
mediated by loss of MMR, which displays aphidicolin (Ap) drug-resistant mechanism by sensitizing 
cancer cells depending on cellular remote reactions. These cellular remote reactions transit into contact 
biochemical reactions causing the above described mechanisms of bypass DNA replication pathway in 
drug resistance in situation of loss MMR.  
b. Footnote: The advantage of the combination very light cytotoxic effects of the small dosage 
cytotoxic drug with the offered method cancer disease treatment is that the offered method cancer 
disease treatment leads to depression of cancer tumor metabolism due to suppression anabolic 
processes, i.e. suppression of mismatch repair (MMR) function and expression catabolic pathway. It 
was exhibited in Moreland NJ et al. experiments [35] with the mediated drug resistance by loss of MMR 
and received aphidicolin (Ap) sensitizing drug-resistant cancer cells via bypass of DNA polymerases. 
However it can affirm that the advantage of the combination very light cytotoxic effects of the small 
dosages of cytotoxic drug with the offered method cancer disease treatment is similar to above 
described mechanism destruction depressed cancer metabolism with small dosage of cytotoxic drugs 
over suppression active cancer metabolism with great dosage cytotoxic drugs in up-to-date methods of 
cancer therapy.  
4.1.6 Role of DNA mismatch repair (MMR) function and p53 function in drugs resistance 
Lin X et al. [36] experiments exhibit that DNA mismatch repair (MMR) function and p53 function are 
major determinants of the rate of cisplatin resistance: Loss either MMR or p53 alone increased the rate 
of resistance to cisplatin.  
Lin X et al. [37] and Yanamadala S et al. [38] experiments exhibit that inhibition of DNA polymerase 
zeta via suppression of REV3 subunit, which eliminates the rate of cisplatin resistance, observed in the 
MLH1-deficient cells.  
Moreover Yanamadala S et al. [38] expressed opinion that MMR proteins can bind to certain DNA 
lesions and signal p53 and create apoptosis by an unknown mechanism, using both alkylating agents 
and H2O2 which caused significant inhibition of mRNA synthesis in MLH1-expressing but not in 
MLH1-deficient cells. They suggest a novel mechanism of MLH1 in the induced p53 and apoptosis by 
inhibiting RNA polymerase II and influencing on damaged DNA templates.  
Also Stubbert LJ et al. [39] indicate that the transcription-coupled nucleotide excision repair 
(TC-NER) play a prominent role in determining the sensitivity of tumour cells to cisplatin even in the 
absence of p53 and DNA mismatch repair.  
a. Mechanisms of experiments outcomes: DNA polymerase zeta takes part in somatic 
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hypermutation of immunoglobulin genes, i.e. pathologic anabolic processes. Unlike DNA polymerase 
zeta, the mismatch repair (MMR) function and p53 prevent pathologic anabolic processes of excessive 
proliferative processes, exerting development of normal cellular cycle via maintenance balanced 
anabolic and catabolic processes in G2/M phases of cellular cycle. Thus expression DNA polymerase 
zeta and expression proficient mismatch repair (MMR) function or p53 cause different chemical 
potentials (µ) which induce the cellular capacitors into inverse cellular operations [8, 10]. Thus 
inhibition DNA polymerase zeta eliminates the increased rate of cisplatin resistance, induced via 
mechanism of MLH1-deficient cells (see above), due to inhibition excessive pathologic anabolic 
processes which observed in acting of DNA polymerase zeta.  
b. Footnote: The advantage of the combination very light cytotoxic effects of the small dosage 
cytotoxic drug with the offered method cancer disease treatment is that the offered method cancer 
disease treatment leads to depression of cancer tumor metabolism due to suppression excessive 
anabolic processes, i.e. inhibition of DNA polymerase zeta and partial suppression both mismatch 
repair (MMR) function and p53 function. The inhibition of DNA polymerase zeta and partial 
suppression either mismatch repair (MMR) function or p53 function of tumor suppressor causes 
expression of the small dosages of cytotoxic drug (cisplatin) operation. Thus it can affirm that the 
advantage of the combination very light cytotoxic effects of the small dosages of cytotoxic drug 
(cisplatin) with the offered method cancer disease treatment is similar to above described mechanism 
suppression depressed cancer metabolism with small dosage of cytotoxic drugs over suppression 
active cancer metabolism with great dosage cytotoxic drugs in up-to-date methods of cancer therapy.  
4.1.7 Investigating of anticancer agents Minor groove binders (MGBs) 
Investigating the interesting class of anticancer agents Minor groove binders (MGBs), Fedier A et al. 
[40] have chosen Brostallicin which is a synthetic O±-bromoacrylic MGB. DNA minor groove binders 
(MGBs) agents are the class of anticancer agents highly effective in variety of human cancers. Just the 
outcomes of their researches reveal that brostallicin-induced cytotoxicity does not depend on functional 
DNA MMR. Besides, Fedier A et al. [40] note that Brostallicin does not alkylate DNA per se but operate 
through the interaction with GSH/GST system. Moreover all tumor cells are characterized with higher 
glutathione (GSH) and glutathione-S-transferase (GST) levels, according to data Geroni et al [41]. Also 
glutathione (GSH) is found in cellular wall, and GST enzyme catalyzes GSH peroxydase activity, which 
lead to the detoxification of lipid and nucleic acid hydroperoxides, according to data Waxman DJ [42]. 
Also Waxman DJ [42] notes that GST enzyme exhibit a ligand binding function, which involves the 
non-covalent binding such substrate as heme, bilirubin, various steroids, and some lipophilic anticancer 
drugs.  These investigations show that cytotoxic effects of Minor groove binders (MGBs) of 
Brostallicin does not depends on DNA mismatch repair (MMR) mechanisms [40], and the cytotoxic 
effect MGB agent occurs through GSH/GST system of cellular wall and cytoplasm [41, 42].  
a. Mechanisms of experiments outcomes: Causing cytotoxic effects by Brostallicin via Minor 
groove Binders (MGBs), the changed GSH/GST systems of cellular wall and cytoplasm influence on 
cellular chemical potentials (µ) of cellular capacitors [9, 10] which don’t depends on DNA mismatch 
repair (MMR) mechanisms. Thus the cytotoxic effects by Brostallicin via Minor groove Binders 
(MGBs) take part in cellular remote reaction through GSH/GST systems of cellular wall and cytoplasm, 
which involved also in neutralisation of ROS/H2O2/free radical in quiescent G0 and G1/S phases 
cellular cycle, detaining as processes DNA replication in G2/M phases cellular cycle as well as tumor 
excessive proliferative processes [10]. Then the cellular remote reaction transits into contact reaction [9, 
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10], as for recognizing substance of cytotoxic drug as well as for exerting subsequent processes of 
resistance to cytotoxic drug.  
b. Footnote: The advantage of the combination very light cytotoxic effects of the small dosage 
cytotoxic drug (Brostallicin) with the offered method cancer disease treatment is that the offered 
method cancer disease leads to depression of cancer tumor metabolism due to suppression anabolic 
processes. The remote cellular reactions between depressed cells of cancer tumor and cytotoxic effect 
of Brostallicin, which are accomplished due to system of cellular capacitors operation fulfilling 
interplay between nucleus capacitors, mitochondria capacitors and other organelle capacitors 
connecting with cellular capacitors [10], precede contact reactions cells on cytotoxic drug Brostallicin 
[9, 10]. Remote cellular reactions of cancer depressed cells don’t prevent to accept the substance of 
cytotoxic drug Brostallicin by cancer cells because the depressed cancer cells in condition of 
Prolonged medical Starvation need for supplemental substances for their metabolism and maintenance 
stability basophilic chemical potential of their cytoplasm (µ) [9]. Therefore remote reaction of 
depressed cancer cells in condition of Prolonged medical Starvation of the offered method cancer 
disease treatment don’t cause drugs resistance. Thus the cytotoxic effects of the small dosage 
Brostallicin in contact reaction become stronger in condition of cancer cells depression over the 
suppressed anabolic processes of cancer cells by great dosage cytotoxic drug in the state of cells 
activity in modern methods cancer therapy, which show the similar cytotoxic effects as on hormonal 
cells and immune cells of an organism as well as on tumor cells. Damage hormonal and immune 
defensive reactions of an organism can lead as to recurrence cancer disease after some medical 
remissions, i.e. palindromia of cancer development, and as well as to resistance to anticancer drugs as 
the result of intensive anticancer chemotherapy with great dosages of cytotoxic drugs in cancer 
therapy. Just the mechanisms of offered method cancer treatment don’t damage immune and hormonal 
systems and don’t cause drug resistance and recurrence cancer disease after some medical remissions.   
4.1.8 Role RAS/RAF/ERK pathway in drugs resistance 
Piscazzi A et al. [43] have found that the essential activation of the RAS/RAF/ERK pathway may lead 
to resistance to sunitinib in thyroid carcinoma cells, although sunitinib inhibits selectively cell 
proliferation inducing cell cumulation in the G0-G1 phase and inhibits the phosphorylation of ERK1/2 
in both KRAS/BRAF wild-type thyroid cancer cells and in tumor cells harboring the RET/PTC 
rearrangement. Furthermore they described that the activation of RAS/RAF/ERK signaling in 
KRAS/BRAF wild-type cells by transfection of the R12 HRAS or V600E BRAF mutants or 
stimulation with epithelial growth factor resulted in the loss of responsiveness to sunitinib, whereas 
pharmacological inhibition of MAPK kinase activity resulted in the reset sensitivity of KRAS- or 
BRAF-mutated cells to the multikinase inhibitor.  
Also Tzu-Hurng Cheng et al. [44] researches exhibit that RAS/RAF/ERK kinase pathway regulates 
extracellular signal due to mediated of cyclic strain by ROS. Extracellular signals induce endothelin-1 
gene.  
a. Mechanisms of experiments outcomes:  Just ROS/H2O2/Free radicals promote processes 
replication in G2 phase cellular cycle exerting process proliferation which is also induced by 
endothelin-1 gene [10]. These excessive processes of cancer metabolism lead to disbalance between 
extracellular chemical potential (µextracell) and intracellular chemical potential (µintracell), due to 
excessive expression RAS/RAF extracellular proteins. This disbalance causes inflow substances from 
extracellular medium into intracellular medium, according to Theorell formula, exerting G1/M phases 
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cellular cycle for excessive cancer proliferative processes [3] (Figure 1). Disbalance between 
extracellular chemical potential and intracellular chemical potential exerts immune calls activity. The 
influences of immune cells via their cellular capacitors operations on sunitinib molecule promote 
suppression of sunitinib activity and cause resistance to sunitinib via immune remote and contact 
reactions [8, 9]. The Ras-Raf-MEK-ERK pathway or MARK/ERK pathway is formed owing to 
suppression cytotoxic effect of sunitinib [8, 9]. Thus these investigations confirm the mechanism of 
excessive expression RAS/RAF/ERK owing to immune cells reaction on cytotoxic drug substances 
after some remissions of cancer disease. 
4.2 Discussions of the mechanisms decrease of medical drugs efficiency via 
gene amplification or epigenetic changes due to treatment with great 
dosage of cytotoxic drugs  
4.2.1 General mechanism of decrease of medical drugs efficiency in palindromia. i.e. recurrence 
disease after cancer disease remission 
Suppression medical drugs activity occurs after multiple remissions of cancer disease, but suppression 
medical drugs activity does not occur in the beginning of the treatment by cytotoxic drugs. Thus 
mechanism of immune responses is appeared after remote reactions across distance via producing 
immune rearrangement in the immune cells due to multiple use anticancer drugs leading to cancer 
disease remission. Then remote reactions transit into contact phase of immune reactions which destroy 
these anticancer drugs causing decrease of medical drugs efficiency [9].  
4.2.2 Interactions between gene amplification in cancer cells and immune response on cytotoxic 
drug in mechanisms of decreased drug efficiency 
Oliveras-Ferraros C et al., [45] have evaluated the connection of HER2 gene amplification with 
resistance to the EGFR (HER2)-targeted of cetuximab antibody and response to combination therapies 
against EGFR and HER2 in wild-type KRAS tumor by patients with colorectal cancer. They noted 
that cetuximab-refractory wild-type KRAS squamous cell carcinoma (SCC) can be fully restored by 
the anti-HER2 monoclonal antibody.  
a. Footnote: Thus this investigation has determined the connected resisting mechanisms 
amplification of HER2 gene and immune response of the EGFR (HER2)-targeted cetuximab antibody 
in wild-type KRAS tumor of patients with colorectal cancer. It is quite true these interactions between 
gene amplification in cancer cells and immune response to cytotoxic drug in mechanisms of decreased 
drug efficiency. Thus cetuximab suppression due to immune cells reaction exerts gene amplification 
that is the result of influence suppressed cytotoxic drug on DNA gene.   
4.2.3 Clinical investigation of interactions between SKP2 gene amplification and SKP2 
immune-expression  
Li CF et al. [46] have studied clinical aggressiveness of myxofibrosarcoma and evaluated interactions 
between SKP2 gene amplification and SKP2 immune-expression for prognosis and independently 
predictive of this disease.  
a. Footnote: Indeed the study of influences on gene amplification due to immune expression is 
most important for clinical purposes regarding prognosis of cancer disease.  
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4.2.4 Studies of epigenetic changes in cancer tumor 
Describing epigenetic changes in cancer tumors, Zeller C and Brown R [47] expressed doubts: 
“Aberrant DNA methylation at CpG islands and associated epigenetic silencing are observed during 
the acquisition of drug resistance. However, it remains unclear whether all of the observed changes 
are drivers of drug resistance, causally associated with response of tumors to chemotherapy, or are 
passenger events representing chance of DNA methylation changes”.  
a. Footnote: The DNA epigenetic changes in cancer cells could appear at current cellular cycle 
phases of cancer development due to oncogene influences, which were subjected to immune 
responses due to cellular capacitors of immune cells operations via remote cellular reactions, owing to 
resonance waves, transiting into contact cellular reactions and suppressing cytotoxic drug (as strange 
object), that results in epigenetic changes in DNA of cancer cells owing to influence of suppressed 
cytotoxic drugs. Thus it occurs resistance to cytotoxic drugs after a phase of cancer disease remission 
and lead to recurrence cancer disease [8, 9, 10].  
4.2.5 Role of extracellular superoxide dismutase (EcSOD) in cancer metabolism 
Studying the role of extracellular superoxide dismutase (EcSOD) in lung cancer, Teoh-Fitzgerald ML 
et al., [48] found that air respiration pathway in normal epithelial cells expressed through EcSOD and 
have an unmethylated promoter, whereas lung cancer cells displayed aberrant promoter 
hypermethylation and decreased chromatin accessibility. EcSOD is considerably lower in lung tumors 
than in normal tissue, and EcSOD promoter is hypermethylated in adenocarcinomas as compared with 
normal lungs. Furthermore re-expression of EcSOD attenuates malignant phenotype of lung 
carcinoma cells, decreasing invasion and survival considerably. However loss of EcSOD expression 
in lung cancer is the result of EcSOD promoter methylation leading to loss of heterozygosity (LOH) 
of EcSOD. It was suggested that early loss EcSOD activity may contribute to extracellular matrix 
(ECM) remodeling causing malignant progression.  
a. Footnote: It is known that ROS/H2O2/Free radicals create cellular replication in G2 phase cellular 
cycle causing proliferative processes [10, 11]. However extracellular superoxide dismutase (EcSOD) 
does not suppress capability of intracellular superoxide dismutase in norm. Just prolonged treatment 
with cytotoxic drugs leads to the epigenetic changes of EcSOD hypermethylation causing by 
hypermethylated EcSOD promoter. The epigenetic inactivation of extracellular superoxide dismutase 
(EcSOD), due to aberrant promoter hypermethylation operation, should activate intracellular 
superoxide dismutase maintaining difference chemical potentials and charges on inner and outer 
cellular membranes for cellular capacitors operation [9]. Intracellular superoxide dismutase exerts 
processes DNA replication in norm due to promoting intracellular dismutation of superoxide [O2*-] 
converting superoxide into hydrogen peroxide [H2O2] and following into free radicals, which advance 
G2 phase cellular cycles of cancer cells [9, 10, 11]. The epigenetic changes can appear as the result of 
immune responses on cytotoxic drug which lead to violation of cytotoxic drugs. Then such cytotoxic 
drugs cause loss of EcSOD due to EcSOD promoter methylation and loss of heterozygosity (LOH) of 
EcSOD which lead to malignant progression and drugs resistance after a phase of cancer disease 
remission, causing recurrence cancer disease.  
4.2.6 The investigations of role epigenetic changes in decrease cancer efficiency 
Investigating operations of several cytotoxic drugs as azacitidine (Vidaza), decitabine (Dacogen), 
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vorinostat (Zolinza), and romidepsin (Istodax), Boumber Y and Issa JP [49] inquired: “Epigenetics in 
cancer: what's the future?”. Describing expected results of these drugs combination in clinical trials 
with DNA methylation inhibitors and histone deacetylase inhibitors, the authors expressed doubt: 
“unclear mechanisms of response and resistance, and rare responses in solid tumors”.  
a. Footnote: Just the mechanism decrease drugs efficiency after intensive chemotherapy with great 
dosage cytotoxic drugs and multiple remissions, causing epigenetic changes, depends on immune 
cells remote reactions on these drugs and epigenetic changes due to influences cellular remote 
reactions of immune cells on cancer DNA via intensive cytotoxic chemotherapy. Indeed cellular 
capacitors of immune cells react on cytotoxic drugs and cause suppression them. The suppressed 
cytotoxic drugs cause epigenetic changes in cancer nuclei, creating rearrangement nucleus DNA 
chemical structure of cancer cells. Thus immune cells become sensitive property to cytotoxic drugs 
causing suppression of cytotoxic drugs and drugs resistance after cancer disease remission.  
4.2.7 Investigations of targeting cancer tumor by tumor suppressors genes 
Gramling S et al. [50] noted that pharmacologically targeting cancer tumor by tumor suppressor genes 
has not been fruitful, because many tumor suppressors genes and oncogenes are irreversibly both 
commonly altered or entirely deleted during carcinogenesis, thereby making it difficult to restore gene 
function.  
a. Footnote: Indeed many tumor suppressors genes and oncogenes operate as primers of 
oncogenesis . Just the oncogenesis advances according to Glansdorff and Prigogine theory resulting in 
nonlinear pathologic development thermodynamic system of an organism [8]. They can cause small 
counteractions of anticancer drugs efficiency. However these counteractions are not mechanisms of 
cancer drug resistance after multiple remissions of cancer disease, but such suppression medical drug 
can occur only in the beginning of the chemotherapy treatment. Furthermore the other such samples 
as putative tumor suppressor gene, anticancer protein BRM, a key SWI/SNF chromatic remodeling 
complex subunit, which direct and limit the execution of specific cellular programs such as 
differentiation and growth control, are inactivated in many tumor types according to Gramling S. et al. 
data [50]. Hence Gramling S. et al. reply that targeting tumor by suppressor genes is not fruitful [50]. 
Thus the mechanisms of tumor suppressors miRNAs, as well as the other tumor suppressors, can not 
be the main cause decreasing cancer drugs efficiency after multiple remissions of cancer disease. Only 
suppressed cancer development die to use of offered “Polonged medical starvation”, which is also 
treated by decreased dosage cytotoxic drugs, prevents as resistance to cytotoxoc drugs as well as 
recurrence cancer disease after some disease remissions. 
4.2.8 Investigations of participation immune mechanisms in decrease cancer efficiency  
Studying antitumor efficiency of cisplatin Li X et al. [51] have noted: “despite of extraordinary 
activities of cisplatin against a variety of solid tumors, cis-Dichlorodiamminoplatinum (II) (cisplatin) 
has demonstrated capability to reduce the toxicity and enhance the circulation time of cisplatin in the 
clinical efficacy. Just cisplatin was incorporated into the nanoparticles with high encapsulation 
efficiency in core-shell structure nanoparticles, which were prepared from block copolymer of methoxy 
poly(ethylene glycol)-polycaprolactone (mPEG-PCL). They concluded that cisplatin-loaded 
nanoparticles exhibited superior antitumor effect by delaying tumor growth [51]. When this drug was 
delivered intratumorally, significant improvement was not observed. Therefore cisplatin was 
administrated intraperitoneally as opposed to action of free cisplatin.  
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a. Footnote: Thus these investigations prove participation peritoneal immune mechanism of 
reticuloendothelial system in action of cisplatin for anticancer efficiency.  
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